-
REAL-WORLD COMPARATIVE OUTCOMES AND COSTS OF SGLT-2 INHIBITORS VERSUS DPP-4 INHIBITORS IN TYPE 2 DIABETES PATIENTS WITH HEART FAILURE
Mar 18, 2026, 21:38 PM -
CAUSAL AI IN EPIDEMIOLOGY AND HEALTHCARE: CONCEPTS AND METHODOLOGIES
Mar 18, 2026, 21:38 PM -
PREDICTING CHRONIC KIDNEY DISEASE IN PATIENTS WITH OBESITY: A PREDICTIVE MODELING APPROACH FOR PREVENTIVE CARE
Mar 18, 2026, 21:38 PM -
DISCREPANCIES BETWEEN GUIDELINE RECOMMENDATIONS AND REGULATORY APPROVALS IN MULTIPLE MYELOMA - IMPORTANCE OF EVIDENCE STRATIFICATION OF A LIVING SYSTEMATIC LITERATURE REVIEW (SLR)
Mar 18, 2026, 21:38 PM -
REAL-WORLD (RW) DISEASE PROGRESSION AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE UNITED STATES (US)
Mar 18, 2026, 21:38 PM -
TOLERABILITY PATIENT-REPORTED OUTCOMES IN FDA ONCOLOGY NEW DRUG APPROVALS (2021-2025)
Mar 18, 2026, 21:38 PM -
A LIFETIME COST-UTILITY ANALYSIS OF IGLARLIXI VERSUS IDEGASP IN TYPE 2 DIABETES IN TURKIYE
Mar 18, 2026, 21:38 PM -
PRODUCTIVITY LOSSES AFTER MISCARRIAGE: A PROSPECTIVE COHORT ANALYSIS USING THE IMTA PRODUCTIVITY COST QUESTIONNAIRE
Mar 18, 2026, 21:38 PM -
COST-UTILITY MODEL OF MATERNAL RSV VACCINATION FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
RELATIONSHIP BETWEEN IMPROVEMENT IN LUNG FUNCTION AND SYMPTOMS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH DUPILUMAB
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF CARDIOVASCULAR BENEFIT OF SEMAGLUTIDE VERSUS TIRZEPATIDE IN PATIENTS WITH OVERWEIGHT OR OBESITY IN CHINA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF CDK4/6 INHIBITORS FOR HR+/HER2- METASTATIC BREAST CANCER IN KAZAKHSTAN
Mar 18, 2026, 21:38 PM -
COMPARATIVEEFFECTIVENESS OF ANTIBIOTICS PLUS SUHUANG ZHIKE CAPSULES VERSUS ANTIBIOTICS ALONE FOR COUGH USING REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
ASSESSING THE ABILITY OF THE EQ-5D-5L TO CAPTURE LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPACTS OF HEREDITARY ANGIOEDEMA ATTACKS
Mar 18, 2026, 21:38 PM -
UNDERSTANDING DISEASE COMPLEXITY IN GRAVES’ DISEASE: A POPULATION-BASED NETWORK ANALYSIS OF COMORBIDITIES
Mar 18, 2026, 21:38 PM -
THERAPEUTIC ROLE OF ALISKIREN MONOTHERAPY IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTIHYPERTENSIVE AND ANTIPROTEINURIC EFFECTS
Mar 18, 2026, 21:38 PM -
DESCRIBING THE ROLE OF CAREGIVERS IN ATTR-CM: A SECONDARY ANALYSIS OF SURVEY DATA FROM GERMANY AND SPAIN
Mar 18, 2026, 21:38 PM -
PERCEIVED CLINICAL VALUE AND COST TRADE-OFF IN PSYCHOLOGY A REAL-WORLD ANALYSIS BASED ON PROMS, PREMS, AND COSTS
Mar 18, 2026, 21:38 PM -
REAL-WORLD RISK OF ACUTE KIDNEY FAILURE AFTER SACUBITRIL/VALSARTAN VS ARB AMONG ADULTS =65 WITH HEART FAILURE
Mar 18, 2026, 21:38 PM -
SHAREHOLDERS AND COMMON OWNERSHIP IN THE MARKET FOR MONOCLONAL ANTIBODIES: A NETWORK ANALYSIS
Mar 18, 2026, 21:38 PM
